Impact of the 2025 NCCN Definition Change for Very High‐Risk Prostate Cancer on Surgical Outcomes After Robot‐Assisted Radical Prostatectomy: A Retrospective Cohort
International Journal of Urology · 2026
DOI: 10.1111/iju.70366 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Noriyoshi Miura und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Robotic Surgical Procedures, Neoplasm Recurrence, Local. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Objectives
In 2025, the National Comprehensive Cancer Network (NCCN) updated the definition of very high‐risk (VHR) prostate cancer to include individuals meeting at least two of the following: clinical stage ≥ T3, prostate‐specific antigen ≥ 40 ng/mL, and Gleason Grade Group (GG) ≥ 4. This revision alters group classification and may impact surgical outcomes. We aimed to compare oncological outcomes under the earlier and 2025 definitions in individuals undergoing robot‐assisted radical prostatectomy (RARP) without perioperative systemic therapy.
Methods
We retrospectively reviewed 1879 individuals who underwent RARP at two institutions between July 2012 and November 2022. Of these, 641 classified as high risk or above were analyzed: historical high risk (Group 1: n = 377), reclassified from VHR to high risk (Group 2: n = 119), and VHR per 2025 criteria (Group 3: n = 145).
Results
The median follow‐up was 59.8 months. Five‐year biochemical recurrence‐free survival rates were 71.1%, 44.7%, and 29.8%; metastasis‐free survival rates were 99.6%, 94.1%, and 88.9% for the three groups, respectively. Group 2 showed worse outcomes than Group 1. Exploratory analyses indicated that within Group 3, having > 4 biopsy cores with GG 4–5 was associated with significantly worse recurrence outcomes, whereas those without this factor had results closer to Group 2.
Conclusions
In conclusion, both the revised high‐risk and VHR categories include heterogeneous populations. Refinement of risk stratification in the surgical setting may help identify subsets requiring tailored perioperative and multimodal strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan.
- Department of Urology, St. Luke's International Hospital, Tokyo, Japan.
ORCID-Profile: Noriyoshi Miura, Yuki Miyauchi
Zitieren
APA
Miura, N., Shimbo, M., Shishido, K., Nobumori, S., Sugihara, N., Sawada, T., Haga, S., Arai, H., Nishida, K., Arai, O., Onishi, T., Watanabe, R., Nishimura, K., Fukumoto, T., Miyauchi, Y., Kikugawa, T., Nishino, T., Endo, F., Hattori, K., & Saika, T. (2026). Impact of the 2025 NCCN Definition Change for Very High‐Risk Prostate Cancer on Surgical Outcomes After Robot‐Assisted Radical Prostatectomy: A Retrospective Cohort. International Journal of Urology. https://doi.org/10.1111/iju.70366
Vancouver
Miura N, Shimbo M, Shishido K, Nobumori S, Sugihara N, Sawada T, et al. Impact of the 2025 NCCN Definition Change for Very High‐Risk Prostate Cancer on Surgical Outcomes After Robot‐Assisted Radical Prostatectomy: A Retrospective Cohort. International Journal of Urology. 2026. doi:10.1111/iju.70366
BibTeX
@article{Miura2026,
author = {Miura, Noriyoshi and Shimbo, Masaki and Shishido, Kensuke and Nobumori, Shota and Sugihara, Naoya and Sawada, Takatora and Haga, Shunsuke and Arai, Haruna and Nishida, Keigo and Arai, Osuke and Onishi, Tomoya and Watanabe, Ryuta and Nishimura, Kenichi and Fukumoto, Tetsuya and Miyauchi, Yuki and Kikugawa, Tadahiko and Nishino, Takato and Endo, Fumiyasu and Hattori, Kazunori and Saika, Takashi},
title = {Impact of the 2025 NCCN Definition Change for Very High‐Risk Prostate Cancer on Surgical Outcomes After Robot‐Assisted Radical Prostatectomy: A Retrospective Cohort},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70366}
}
EUVIMED